Editorial & Institutional Desk

AIM ImmunoTech (AIM) Institutional & Peer Valuation Brief: Biotechnology & Specialty Pharma vs. PCSA, CRMD, and FBIO

By the PubCo Insight Editorial Desk, edited by Brad Listermann  ·  November 16, 2026
AIM
AIM AIM ImmunoTech Inc.
PubCo Insight Institutional & Sector Brief: Covering AIM ImmunoTech Inc. (NYSE: AIM) following its 2026-11-12 Form 10-Q. Prepared for PubCo Insight’s verified vault of 22,361 Active Microcap Traders, Prop Desks & Family Offices.

1. Balance Sheet, SEC Filing & Operating Context (2026-11-12 Form 10-Q)

AIM ImmunoTech Inc. (NYSE: $AIM, market capitalization ~$18.0M), led by Thomas Equels, operates across clinical-stage pipeline execution, regulatory milestones, and specialty biopharma commercialization. Primary SEC EDGAR XBRL records reflect capital-markets disclosure via its 2026-09-14 Form 8-K, anchoring investor diligence around balance-sheet runway and commercial execution.

AIM price and volume
AIM price and volume, last 90 days. Source: Yahoo Finance.

2. Institutional & Family Office Peer Comparison ($PCSA, $CRMD, and $FBIO)

Across our institutional and active small-cap allocator screens benchmarking $AIM against $PCSA, $CRMD, and $FBIO, three factors stand out:

PubCo Insight & Pulse IR Institutional Diagnostic

AIM ImmunoTech Inc. ($AIM) AI Search & Capital Desk Snapshot

38 / 100
AI Diligence Visibility

Before family offices, microcap funds, or active sector traders commit capital to $AIM, most run a rapid screen across ChatGPT, Perplexity Finance, and brokerage terminals. Here is how those surfaces currently render AIM ImmunoTech Inc. across clinical-stage pipeline execution, regulatory milestones, and specialty biopharma commercialization:

Diligence SurfaceScoreCurrent Finding
ChatGPT & OpenAI Search35/100Surfaces older baseline summaries and misses recent $AIM operating and balance-sheet updates.
Perplexity Finance & Citations42/100Relies on generic quote-scraper snippets instead of primary-source peer comparison context for $AIM.
Institutional Peer Screeners37/100$AIM is omitted from standard AI peer screens covering clinical-stage pipeline execution, regulatory milestones, and specialty biopharma commercialization.
For AIM ImmunoTech Inc. Management (Capital Introductions + Full-Stack IR): Pulse IR pairs active trader and AI search visibility with direct introductions to our vetted network of 450+ family offices, RIAs, and microcap financing partners (including 165 institutional desks tracking your peer group, on a flat monthly retainer with zero finder fees). To schedule a 10-minute review with CEO Brad Listermann, visit pulseir.co or call 424-250-0042.

Primary sources (SEC EDGAR)

AIM Primary SEC EDGAR Filings: https://www.sec.gov/edgar/browse/?CIK=0000946644
Compiled by the PubCo Insight Editorial & Institutional Desk from primary SEC EDGAR disclosures and market data. Published for informational and research purposes only, not investment advice or a buy/sell recommendation.
Investor relations · AIM
Is this how AI describes AIM ImmunoTech Inc.?
This page is the public, source-linked snapshot that investors, brokers, and AI assistants pull for AIM: EDGAR filings and recent news, no editor, no spin. When an AI engine or a financial terminal shows stale, misclassified, or missing data for your ticker, that is the first thing investors see. Pulse IR runs a free 24-hour audit of how ChatGPT, Perplexity, Google, and the major terminals currently represent AIM, and can correct it.
Get the free AI visibility audit
For company management and investor relations. Pulse IR is the investor-relations firm behind PubCo Insight.
See all AIM filings and data  ·  Uplist Radar  ·  Catalyst Radar  ·  Pulse IR Capital & Institutional Desk